For instance, pamrevlumab, targeting connective tissue growth factor (CTGF) expressed by CAFs, aims to reduce tumor fibrosis and stiffness, thereby enhancing immune cell infiltration and promoting anti-tumor activity [91, 92]. The gene discussed is CCN2; the disease is neoplasm.